RxDoctor Payments Data

Georgia Henry, DO

Family Medicine · Middletown, DENPI 1225533375

Payments from drug & device makers

$771in general payments, 2019–2025

Across 22 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$274
  • AbbVie$114
  • Novo Nordisk$113
  • Viiv Healthcare Company$63
  • Exact Sciences$60
  • Astellas Pharma US Inc$32
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$771 in reported general payments places this provider in the 65th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$103,077
Medicare patients
308
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$60,256
JardianceEmpagliflozin43$50,382
EliquisApixaban43$47,781
Atorvastatin Calcium210$2,431
Rosuvastatin Calcium108$1,626
Gabapentin58$1,483
Valsartan19$1,437
Omeprazole82$1,345
Ezetimibe44$1,308
Amlodipine Besylate184$1,212
Levothyroxine Sodium101$1,005
Tamsulosin Hcl38$923
Losartan Potassium94$918
Metoprolol Succinate61$840
Albuterol Sulfate HfaAlbuterol Sulfate42$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$60,25642 claims
AbbVieSynthroid$114$55031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 352 family medicine providers in Delaware.

Other family medicine in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →